Global biopharmaceutical firm Merck announced that the company’s Phase III trial for a potential treatment for pneumococcal disease in infants succeeded in meeting key safety, tolerability, and immunogenicity endpoints in the first 30 days.
Shares of Aprea Therapeutics plunged after the Boston-based company announced a late-stage cancer combination treatment failed to meet the primary endpoint of complete remission rate.
The U.S. Food and Drug Administration approved MorphoSys and Incyte’s Monjuvi (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
Just a day after Hanmi Pharmaceutical announced a deal with Genentech, Boehringer Ingelheim terminated a license deal because of patient deaths.
Tonix Pharmaceuticals Holding Corp. said it would stop developing its drug for fibromyalgia after the treatment failed in a late-stage trial.
Irish drugmaker Shire Plc said it would buy the rights to an experimental bowel drug from Pfizer Inc to bolster its pipeline of gastrointestinal treatments.
Novartis received breakthrough therapy designation from the U.S. Food and Drug Administration for an investigational treatment for newly-diagnosed FLT3-mutated acute myeloid leukemia, the Swiss drugmaker said on Friday. Patients who received PKC412, also called midostaurin, combined with standard induction and consolidation chemotherapy experienced what Novartis called “a significant improvement in overall survival”. With the announcement, […]
The U.S. Food and Drug Administration has granted breakthrough therapy designation to AstraZeneca’s biggest new drug hope durvalumab as a treatment in bladder cancer, the drugmaker said on Wednesday. The experimental medicine is a so-called PD-L1 therapy that fights cancer by boosting the immune system. Breakthrough therapy designation expedites the development and review of […]
The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
New data from a midstage trial show that Celldex Therapeutics Inc’s experimental brain cancer vaccine, combined with standard therapy, continues to improve chances of survival for patients with recurrent cancer. The updated results sent shares of Celldex up $1.74, or 12 percent, to $16.23 on the Nasdaq. The therapy, designed to enlist the body’s immune […]